Independent Franchise Partners Adds $30M in Solventum Corporation ($SOLV)
Key Points
- Independent Franchise Partners changed its Solventum Corporation ($SOLV) stake by 2.46% last quarter, boosting to 15,733,495 shares worth $1.24 billion.
- Wall Street's consensus rating on $SOLV is Buy and an average price target of $93.92.
- $SOLV last traded around $78.87.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Independent Franchise Partners increased its position in Solventum Corporation ($SOLV) by 2.46% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,733,495 shares of Solventum Corporation after buying 377,804 shares during the quarter. Independent Franchise Partners's holdings in Solventum Corporation were worth $1.24 billion as of its most recent filing.
Solventum Corporation Stock Down 13.4%
Shares of Solventum Corporation ($SOLV) traded around $78.87 on Saturday, down 13.4% for the day.
Solventum Corporation Earnings
Analysts Set New Price Targets
About Solventum Corporation
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
Get Solventum Corporation alerts
New 13F filings, insider trades, and analyst moves on $SOLV, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.